Similar operative outcomes between the da vinci xi ® and da vinci si ® systems in robotic gastrectomy for gastric cancer

Rana M. Alhossaini, Abdulaziz A. Altamran, Seohee Choi, Chul Kyu Roh, Won Jun Seo, Minah Cho, Taeil Son, Hyung Il Kim, Woo Jin Hyung

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Purpose: The robotic system for surgery was introduced to gastric cancer surgery in the early 2000s to overcome the shortcomings of laparoscopic surgery. The more recently introduced da Vinci Xi ® system offers benefits allowing four-quadrant access, greater range of motion, and easier docking through an overhead boom rotation with laser targeting. We aimed to identify whether the Xi ® system provides actual advantages over the Si ® system in gastrectomy for gastric cancer by comparing the operative outcomes. Materials and Methods: We retrospectively reviewed all patients who underwent robotic gastrectomy as treatment for gastric cancer from March 2016 to March 2017. Patients’ demographic data, perioperative information, and operative and pathological outcomes were collected and analyzed. Results: A total of 109 patients were included in the Xi ® group and 179 in the Si ® group. Demographic characteristics were similar in both groups. The mean operative time was 229.9 minutes in the Xi ® group and 223.7 minutes in the Si ® group. The mean estimated blood loss was 72.7 mL in the Xi ® group and 62.1 mL in the Si ® group. No patient in the Xi ® group was converted to open or laparoscopy, while 3 patients in the Si ® group were converted, 2 to open surgery and 1 to laparoscopy, this difference was not statistically significant. Bowel function was resumed 3 days after surgery, while soft diet was initiated 4 days after surgery. Conclusions: We found no difference in surgical outcomes after robotic gastrectomy for gastric cancer between the da Vinci Xi ® and da Vinci Si ® procedures.

Original languageEnglish
Pages (from-to)165-172
Number of pages8
JournalJournal of Gastric Cancer
Issue number2
Publication statusPublished - 2019 Jun

Bibliographical note

Funding Information:
Dr. Woo Jin Hyung has stock in Hutom, received a research grant from Medtronic and GC Pharma, and was a consultant for Ethicon and Verb Surgical. The other authors declare that they have no conflicts of interest.

Publisher Copyright:
© 2019. Korean Gastric Cancer Association.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology
  • Cancer Research


Dive into the research topics of 'Similar operative outcomes between the da vinci xi ® and da vinci si ® systems in robotic gastrectomy for gastric cancer'. Together they form a unique fingerprint.

Cite this